Prospective Study Evaluating the Effect of Repository Corticotropin in the Treatment of Various Nephrotic Syndromes
| Status: | Archived |
|---|---|
| Conditions: | Nephrology |
| Therapuetic Areas: | Nephrology / Urology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | December 2009 |
| End Date: | December 2010 |
To determine if H.P. Acthar Gel (repository corticotrophin) has the same anti-proteinuric
effects seen with the synthetic ACTH analogue in Europe.
Synthetic ACTH (Synacthen Depot) has been used in the treatment of Nephrotic Syndrome in
Europe. It has been proven effective in treating idiopathic membranous nephropathy and other
various diagnoses involving the kidneys. However, Synacthen is not available in the United
States. The only preparation available is the H.P. Acthar Gel (repository corticotrophin)
which has been widely used in the treatment of infantile spasms and has been available
longer than Synacthen. Therefore, we are conducting this study to determine if H.P. Acthar
Gel (repository corticotrophin) is as effective in reducing protein in the urine as seen in
synthetic ACTH in Europe.
We found this trial at
1
site
Click here to add this to my saved trials
